Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Signs Pilot Research Deal with Novartis

NEW YORK, April 19 (GenomeWeb News) - Compugen will study biological interaction networks for Novartis by using a platform for analyzing microarray and other data it intends to develop, the Tel Aviv, Israel-based company said today.

Under the pilot project, Novartis will pay Compugen a one-time fee for the results and obtain exclusive rights to them. Compugen will retain all rights to the platform it plans to develop under the collaboration. Additional information about this platform was not disclosed. Also not immediately clear is how this platform will differ from Compugen's existing LEADS technology, which analyzes array and other data -- inlcuding those supplied by Novartis.

Indeed, in August 2001, Novartis licensed Compugen's LEADS platform and asked the company to design DNA chips. The companies broadened their collaboration to include target validation and RNA interference in September 2002.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.